Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 5/20 | 0.68 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.68 |
| ▸ | HTR3A | P46098 | 2/20 | 0.68 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
| ▸ | EP300 | Q09472 | 1/20 | 0.58 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.58 |
| ▸ | KDM1A | O60341 | 2/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.53 |
| ▸ | HRH1 | P35367 | 1/20 | 0.53 |
| ▸ | GBA1 | P04062 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1475614 | 0.98 | TDP1 (0.70) | SLC6A2SLC6A4HTR3AKCNH2TDP1 | |
| SCHEMBL35429 | 0.89 | SLC6A2 (0.69) | SLC6A2SLC6A4HTR3AKCNH2TDP1 | |
| SCHEMBL27972144 | 0.89 | SLC6A2 (0.69) | SLC6A2SLC6A4HTR3AKCNH2TDP1 | |
| SCHEMBL26668494 | 0.87 | SLC6A2 (0.71) | SLC6A2SLC6A4HTR3AKCNH2TDP1 | |
| SCHEMBL1990800 | 0.86 | TDP1 (0.57) | TDP1 | |
| Tert-Butyl Formate SCHEMBL27911375 | 0.84 | TDP1 (0.54) | SLC6A2SLC6A4HTR3AKCNH2TDP1 | |
| SCHEMBL13096959 | 0.83 | SLC6A2 (0.61) | SLC6A2SLC6A4HTR3AKCNH2TDP1 | |
| SCHEMBL3251306 | 0.82 | SLC6A2 (0.72) | SLC6A2SLC6A4HTR3AKCNH2TDP1 | |
| SCHEMBL10533845 | 0.82 | PARP15 (0.56) | TDP1 | |
| Hydrochloric Acid SCHEMBL3096005 | 0.82 | SLC6A2 (0.59) | SLC6A2SLC6A4HTR3AKCNH2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103179976-A | Glucagon superfamily peptides exhibiting g protein-coupled receptor activity | MARCADIA BIOTECH INC | 2013-06-26 | — | — | CN | claimed |
| US-20130116172-A1 | GLUCAGON SUPERFAMILY PEPTIDES EXHBITING G PROTEIN COUPLED RECEPTOR ACTIVITY | MARCADIA BIOTECH, INC. (US) | 2013-05-09 | — | — | US | claimed |
| EP-2568993-A1 | GLUCAGON SUPERFAMILY PEPTIDES EXHIBITING G PROTEIN-COUPLED RECEPTOR ACTIVITY | Indiana University Research and Technology Corporation (US) | 2013-03-20 | — | — | EP | claimed |
| WO-2011143208-A1 | GLUCAGON SUPERFAMILY PEPTIDES EXHIBITING G PROTEIN-COUPLED RECEPTOR ACTIVITY | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2011-11-17 | — | — | WO | claimed |
| US-4243807-A | CHEMICAL INTERMEDIATES FOR HYPOTENSIVE AGENTS | BOEHRINGER MANNHEIM GMBH (DE) | 1981-01-06 | — | — | US | claimed |
| US-20260022130-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2026-01-22 | — | — | US | disclosed |
| US-12281124-B2 | Heterocyclic compounds as monoacylglycerol lipase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2025-04-22 | — | — | US | disclosed |
| US-20250115571-A1 | OXOPIPERAZINE DERIVATIVES | Inthera Bioscience AG (CH) | 2025-04-10 | — | — | US | disclosed |
| EP-4474017-A2 | NEW HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2024-12-11 | — | — | EP | disclosed |
| US-20240217978-A1 | COMPOUND AS ADENOSINE A2a RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2024-07-04 | — | — | US | disclosed |
| US-20240217978-A1 | COMPOUND AS ADENOSINE A2a RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2024-07-04 | — | — | US | disclosed |
| EP-3837263-B1 | NEW HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2024-07-03 | — | — | EP | disclosed |
| EP-0014928-B1 | PIPERIDINOPROPYL DERIVATIVES, PROCESS FOR THEIR PREPARATION AND MEDICAMENTS CONTAINING THESE COMPOUNDS | Roche Diagnostics GmbH (DE) | 1982-05-05 | — | — | EP | disclosed |
| US-4288442-A | Inhibiting adrenergic β-receptors with piperidinopropyl derivatives | BOEHRINGER MANNHEIM GMBH (DE) | 1981-09-08 | — | — | US | disclosed |
| US-4243807-A | CHEMICAL INTERMEDIATES FOR HYPOTENSIVE AGENTS | BOEHRINGER MANNHEIM GMBH (DE) | 1981-01-06 | — | — | US | disclosed |
| US-4243807-A | CHEMICAL INTERMEDIATES FOR HYPOTENSIVE AGENTS | BOEHRINGER MANNHEIM GMBH (DE) | 1981-01-06 | — | — | US | disclosed |
| US-4243807-A | CHEMICAL INTERMEDIATES FOR HYPOTENSIVE AGENTS | BOEHRINGER MANNHEIM GMBH (DE) | 1981-01-06 | — | — | US | disclosed |
| EP-0014928-A1 | Piperidinopropyl derivatives, process for their preparation and medicaments containing these compounds | Roche Diagnostics GmbH (DE) | 1980-09-03 | — | — | EP | disclosed |
| US-4146630-A | HYPOTENSIVE AGENTS | BOEHRINGER MANNHEIM GMBH (DE) | 1979-03-27 | — | — | US | disclosed |
| US-4086347-A | ANTIALLERGENS, ANTIINFLAMMATORY AGENTS, ANTIEDEMIC AGENTS, HYPOTENSIVES | BOEHRINGER MANNHEIM GMBH (DT) | 1978-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116172-A1 | GLUCAGON SUPERFAMILY PEPTIDES EXHBITING G PROTEIN COUPLED RECEPTOR ACTIVITY | GCGR, GLP1R, GIPR | SLC6A2 2352/4885SLC6A4 2861/4885HTR3A 1189/4885 |
| US-20260022130-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | LIPC, LIPA, LPL | SLC6A2 4083/4885SLC6A4 4451/4885HTR3A 2427/4885 |
| US-12281124-B2 | Heterocyclic compounds as monoacylglycerol lipase inhibitors | LIPC, LPL, MGLL | SLC6A2 4730/4885SLC6A4 4796/4885HTR3A 3297/4885 |
| US-20250115571-A1 | OXOPIPERAZINE DERIVATIVES | CYP3A5, AQP1, AVPR2 | SLC6A2 812/4885SLC6A4 1254/4885HTR3A 401/4885 |
| US-20240217978-A1 | COMPOUND AS ADENOSINE A2a RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | ADORA2A, ADORA1, ADORA2B | SLC6A2 641/4885SLC6A4 743/4885HTR3A 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.